clinical trial · NCT05789082
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Hoffmann-La Roche·phase2·recruiting·n = 320
Non-Small Cell Lung CancerDivarasibPembrolizumabCarboplatinCisplatinPemetrexed
brief summary
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of single-agent divarasib or combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).
started
Jun 20, 2023
primary completion
Jan 29, 2032
completion
Jan 29, 2032
last updated
Apr 20, 2026
official title
A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol